Aurinia Pharmaceuticals Inc (AUPH) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $7. H.C. Wainwright advised their investors in a research report released on Jun 30, 2016.
Aurinia Pharmaceuticals Inc opened for trading at $2.84 and hit $2.92 on the upside on Wednesday, eventually ending the session at $2.87, with a gain of 6.30% or 0.17 points. The heightened volatility saw the trading volume jump to 67,434 shares. Company has a market cap of $93 M.
Aurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate voclosporin which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug administered twice daily. It is structurally similar to cyclosporine A (CsA) but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis (LN). LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease the requirement for life-long dialysis or death. The Company had completed two Phase III studies of voclosporin in patients with moderate to severe psoriasis. The Company had completed a Phase IIb clinical trial of voclosporin in de novo renal transplant recipients. The Company’s wholly owned subsidiaries include Aurinia Pharmaceuticals Inc. and Aurinia Pharma Limited.